+41 91 682 20 40 info@elixi-int.com

Fexinidazole, first oral-only medicine for the treatment of human African trypanosomiasis (HAT), recommended for approval.

EMA’s human medicines committee has adopted a positive opinion for Fexinidazole Winthrop (fexinidazole), the first oral-only medicine (tablets) for the treatment of human African trypanosomiasis (HAT), commonly known as sleeping sickness, due to Trypanosoma brucei gambiense. HAT is a life-threatening, neglected tropical…

Read More

Luxturna (voretigene neparvovec), first treatment option for hereditary retinal dystrophy with mutations of the RPE65 gene recommended for authorisation by EMA

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for the gene therapy Luxturna (voretigene neparvovec), for the treatment of adults and children suffering from inherited retinal dystrophy caused by RPE65 gene mutations, a…

Read More